Jul. 13 at 2:28 PM
$PPCB Clinical development is built through a series of scientific, operational, and regulatory milestones. Over the past few months, PRP has continued advancing across several areas supporting the planned Phase 1b First-In-Human study.
Recent company announcements include:
- Multi-year research collaboration with the Universities of Granada and Jaén.
- PK assay development for the planned Phase 1b study.
- Selection of a European CDMO for GMP manufacturing.
- Target manufacturing timeline announced, including pre-production, engineering run, and planned GMP manufacture.
- Continued preparation of the planned Clinical Trial Application (CTA).
Each milestone serves a different purpose, but together they represent the work required before a therapy can enter clinical studies. We look forward to continuing to share the progress supporting PRP's development pathway.
